Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Signed written informed consent
Female postmenopausal patient (or patient post-ovariectomy) and age ≥18 years Postmenopause ist defined as
* Age ≥ 60 years and natural menopause with menses \> 1year ago or
* FSH and E2 levels in the postmenopausal range or
* Patients who had bilateral ovariectomy (NCCN V.I. 2009)
Histologically confirmed ER+ locally advanced or metastatic breast cancer
You may not be if
Prior treatment with tamoxifen
Suitable to undergo endocrine treatment for ER+ ABC with SERD / sAI
Patient is able to read and understand German
Known hypersensitivity to Faslodex or Exemestane or any compounds of the drugs
Prior treatment with Faslodex 500 mg or Faslodex 250 mg\*
* for patients who receive treatment with Faslodex 500 mg within this observational study. Patients who are included in the exemestane arm may have received prior Faslodex treatment.
Prior treatment with Exemestane for patients who receive treatment with Exemestane within this observational study
Acutely life threatening disease
Treatment with Faslodex 250 mg/month (previously approved dose)
Prior palliative chemotherapy
Clareo Health | A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer
